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The role of cellular immunity as a mediator of protection against disease is gaining recognition,
particularly in regard to the many pathogens for which we presently lack effective vaccines. As a
result, there is an ever-increasing need to understand the T cell populations induced by vaccination
and therefore T cell epitopes responsible for triggering their activation. Although the
characterization and harnessing of cellular immunity for vaccine development is an active area of
research interest, the field still needs to rigorously define T cell epitope specificities, above all, on
a genomic level. New immunoinformatic epitope mapping tools now make it possible to identify
pathogen epitopes and perform comparisons against human and microbial genomic datasets. Such
information will help determine whether adaptive immune responses elicited by a vaccine are both
pathogen-specific and protective, but not cross-reactive against host or host-associated sequences
that could jeopardize self-tolerance and/or human microbiome-host homeostasis. Here, we discuss
advances in genomics and vaccine design and their relevance to the development of safer, more
effective vaccines.
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1. Introduction
Since antiquity, the story of “human against microbe” has been evolving: humans have long
battled against infectious disease, sometimes prevailing, sometimes succumbing and, at
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other times, arriving at a stalemate with unfriendly pathogens. The advent of vaccination,
whereby the immune system is trained to recognize and fight infection without requiring
exposure to the pathogen, gave humans a powerful tool for survival in the evolutionary
tussle between human and microbe. Vaccines save millions of lives, serve as a cost-effective
means of fighting disease by prevention rather than by treatment, and ideally protect against
re-infection. Overall, vaccines represent one of the greatest contributions to public health,
yet there remains a great need to slow or stop the charge of many pathogens that have not
yielded to traditional vaccine development approaches. Here, we discuss the promise of a
genomes-to-vaccine strategy and the importance of emerging genomic data and
immunoinformatics tools to the development of safer, more effective vaccines.

2. Genomes-to-Vaccines
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A genomes-to-vaccine strategy for rational vaccine design rests on the premises that (i) a
minimal set of immunogens capable of inducing a robust and sustained immune response to
a pathogen can be discovered using immunoinformatics, and (ii) administration of these
immunogens together with adjuvant in a suitable delivery vehicle will result in protection
from disease. This diverges from conventional approaches where whole organism vaccines
(live, live attenuated, killed/inactivated) provide more information than the immune system
needs for protection, thereby presenting unnecessary safety risks for activation of undesired
immune reactions. The genomes-to-vaccine approach aims to identify the minimal, essential
information derived from pathogen genomic sequences that is needed to achieve protection
while avoiding unintended and dangerous effects. Using bioinformatic/computational
methods, it is possible to tease out this information, while also taking into account the
sequence data representative of humans, commensal microbial species and infectious
pathogens. Adherents to this approach believe that the minimum essential data is encoded, at
least in part, by T cell epitopes, short peptide sequences that bind major histocompatibility
complex (MHC) proteins and are displayed by antigen presenting cells to T cells, critical
mediators of early processes in adaptive immunity. CD8 and CD4 T cells play an important
role in containing infections and may be critical correlates of protection after re-exposure.
CD4 T cell responses are critical for robust CD8 T cell proliferation and function and for
their differentiation into memory cells [1,2]. Moreover, CD4 T cell responses provide
required help to B cells to produce antibodies that are the mediators of protection in all
currently approved human vaccines [3]. While B cell epitopes undeniably also contribute to
protective immunity, our focus here is on T cell epitope identification and assessment
through computational screening of genomic sequences.
There are four major steps that comprise the genomes-to-vaccine strategy, which can be
thought of as a funneling process (Figure 1) [e.g. 4,5]: (i) Genomes are mined using
computational tools to identify genes that encode proteins with promising antigenic
properties such as secretion, up-regulated expression, reported immunogenicity and
virulence [e.g. 6,7,8]. Alternatively, with no bias introduced by knowledge of protein
function, expression kinetics or localization, complete open reading frame datasets are
analyzed for the reason that the immune system is omnivorous and may present sequences
from any protein antigen to stimulate T cell responses. (ii) Immunoinformatics tools are then
used to discover, within protein sequences, short, linear, putative T cell epitopes. As the
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number of sequenced genomes increases, it becomes increasingly impractical to identify T
cell epitope vaccine candidates by experimental means, even in high-throughput screens.
Robust computational algorithms and hardware, by comparison, can handle the data surge
and expedite the process. (iii) Next, selected sequences are synthesized as peptides and
evaluated for human leukocyte antigen (HLA) binding and antigenicity in survivors of
infection or vaccinees. (iv) Finally, prototype epitope-based vaccines are evaluated for
immunogenicity and efficacy in humanized mice. Epitopes may be formulated as multiple
peptides or as concatamers in the form of DNA or protein vaccines, which elicit CD4 and
CD8 T cell responses [e.g. 9,10,11]. In addition to antigen identification, clinical
development of genome-derived, epitope-based vaccines requires co-formulation of antigens
with adjuvant in a suitable delivery vehicle. As adjuvant and delivery technologies mature in
the broader field of vaccinology, they, too, provide important lessons that will help epitopebased vaccines achieve requirements for clinical approval.
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Having performed this process a number of times [12,13,14,15] our strategy is to require
careful selection of epitopes at the computational phase to maximize the likelihood of
success in bench-based experiments. To enable this computational approach, it is essential to
consider not only the genomic sequence data of the pathogen of interest, but also that of
human and human microbiome genomes.

3. Microbial Genomes
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The Institute for Genomics Research (TIGR), now part of the J. Craig Venter Institute,
sparked the field of genome sequencing in 1995 when it published the first complete
sequence of a living organism, Haemophilus influenzae. That it was possible to overcome
the computational enormity of assembling a shotgunned 1.8 Mb genome represented a major
milestone that heralded the completion of new microbial genome projects in the years that
followed. In recent years, whole genome sequences became available in public databases,
which enabled genomic and proteomic comparisons for the study of large-scale patterns in
pathogenic microbial sequence data that aid in understanding microbial ecology and hostpathogen interactions. In the process, these studies led to the development of algorithms and
computational methods that have become essential to harnessing sequence data for
understanding, preventing and treating infection (see Darren Flower's excellent text,
Bioinformatics for Vaccinology, for a full review of the field [16]). Furthermore, they have
yielded important new concepts of direct import to the field of vaccines that are discussed
below.
Microbial species are comprised of both a set of core and dispensable genes, with the sum of
these two components forming the species pan-genome [17]. The core genome comprises
genes found in all strains of a species. These genes may contain immunogenic elements, or
epitopes, that are highly conserved between pathogens. Conservation may be advantageous,
expanding the breadth of coverage by a vaccine, or disadvantageous, impinging on the
survival of beneficial commensals that possess similar sequences. The dispensable genome
represents genes unique to single strains and those found in two or more, but not all, strains
within a species. These genes can be of great interest to vaccine developers, especially if
they are represented in a large proportion of circulating strains. A comparative genomic
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analysis recently depicted that, because the number of unique genes is so large, the pangenome of a bacterial species can be significantly larger than any single member genome
[18]. Thus, careful, rational selection of vaccine targets becomes one of the most important
first steps in the genome-to-vaccine process.
The breadth of genomes, and their potential for variation over time, remains a significant
concern for genome-to-vaccine developers. Future studies will investigate whether core
genomes are static or dynamic. There are not enough computational data sets for this
determination to be made at present, although initial observations may be made for select
cases. For instance, an analysis of 96 genome sequences derived from two closely related
sympatric sister species of pathogenic bacteria - C. coli and C. jejuni - showed that the core
genome is thought to be resistant to interspecies recombination between the two sister
species, which supports the concept of a finite, species-specific core genome [17]. A finite
genome in this context means that there are unique and cohesive features to each genome
analyzed; these features define genomic identity, and may be of great importance for the
development of species-specific vaccines.
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Examination of genomic content including laterally transferred sequences within and
between species, and core vs. dispensable genome data sets, will help to elucidate further
detail regarding genome plasticity, as well as characteristics and features of each species.
Because evolution of species-specific core genes possibly reflects different adaptive
strategies of that species [17], these analyses could reveal adaptive strategies a species uses
to inhabit, and possibly cause disease in its specific niche. Furthermore, laterally transferred
sequences may impact on immune responses to commensals or other pathogens, if the
sequences contain epitopes highly conserved between species.
Thus, the definition of genomic identity is essential for selection of species-specific antigens
that can provide protection expressly against the pathogen of interest, leading to more
focused vaccine designs and, potentially, improved safety and efficacy. Moreover,
characterization of core genome plasticity over time and geography provides important
information that directly impacts the likelihood that a vaccine will offer protective efficacy
as the pathogen evolves. Antigens selected for T cell epitope identification will ideally be
chosen from stable elements of a genome.
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4. Human Genome
As important as it is to know which epitopes to include in a vaccine, it is just as important to
know which epitopes to exclude (Figure 2). The potential for T cell cross-reaction between
pathogen and human sequences may cause autoimmunity in genetically susceptible
individuals, which is precisely the opposite intent of vaccination. For example, in
individuals with treatment-resistant Lyme arthritis, cross-reactivity between human LFA-1
protein and the Borrelia burgdorferi OspA protein was shown to be the result of similar
MHC-bound peptides derived from these antigens [19]. Interestingly, the recombinant OspA
Lyme disease vaccine, LYMErix®, was withdrawn from the market following patient
complaints about autoimmune side effects, although no direct connection was rigorously
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demonstrated. Nonetheless, this incident sends a cautionary signal to vaccine developers to
consider factors that may lead to autoimmune pathology.
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We have implemented a straightforward approach to limit the possibility of cross-reactivity
and autoimmunity in epitope-based vaccines [20]. Essentially, a BLAST search is performed
with candidate epitope sequences against the human genome. Epitope sequences which are
homologous to components of the human genome are excluded from the epitope data set to
be considered for use in vaccine development, while the remaining “foreign” epitopes can
be safely included in vaccine formulations. Recently, novel human sequences absent from
the existing reference genome have been discovered in different individual genomes,
illustrating that the human genome is also composed of individual-specific and core
sequences [21]. To effectively screen candidate vaccine epitopes for potential crossreactivity in all potential vaccinees, coding sequences in the human pan-genome need to be
considered, when they become available.

5. Human microbiome genomes
NIH-PA Author Manuscript
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Microorganisms that live symbiotically in humans are collectively known as the human
microbiome. Although it is estimated that these microbes outnumber human cells by a factor
of 10 to 1, little is known about the effect these complex human microbial communities have
on human health. The NIH has prioritized the understanding of the human microbiome as
part of its Roadmap for Medical Research and has funded a significant effort to map and
sequence the human microbiome, thus enabling an analysis of its role in human health and
disease [22]. Analysis of the first 178 reference microbial genomes was published this year
by members of the Human Microbiome Project Jumpstart Reference Strains Consortium
[23], not only illustrating, by sheer volume of genomic sequences, the distance we have
come since the first bacterial genome was published, but also facilitating the expedited
development of vaccines. The data also suggest that the impact of vaccination on the human
microbiome may be significant because of the possibility that sequence similarities between
vaccine antigens and the human microbiome can potentially activate T cell-mediated
mechanisms that perturb natural tolerance to commensal organisms and disrupt the natural
symbiosis between human and microbial flora. Identification of such homologous sequences
is important to enable rational design of vaccines that focus on pathogen-specific epitopes
without disrupting the host-microbiome interface (Figure 2).

6. Conclusion
Identification of core and dispensable genes in microbial genomes will not only help to
elucidate the genomic roots of biological patterns inherent in pathogenesis, commensalism
and genome evolution, but also aid in the careful selection of antigens to include and
exclude from vaccines that elicit effective immunity against pathogenic organisms.
Consideration of these concepts in vaccine design will make it possible to preserve the
balance between human and commensal microbial communities, as well as control of
regulatory mechanisms that prevent onset of autoimmune disease. This rigorous evaluation
process will lead to a new generation of vaccines that will be better poised to control and
even eradicate disease.
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Vaccines are an effective means of preventing infectious disease. However, certain vaccines
have been associated, either rigorously or anecdotally, with a number of adverse events and
autoimmune sequelae. Detrimental effects associated with vaccines have raised concerns
with the general public, dissuading some from participating in vaccination programs. The
burden is on the scientific community to continue to conduct research on purported vaccineassociated complications, and to provide the public with reasonable assurances that
recommended vaccines are as safe as possible.
A key issue that requires study is the role of T cells in adverse reactions to vaccines. This is
because there is convincing evidence consistently building over time that demonstrates a
significant role for T cell responses in vaccines that show clinical efficacy through humoral
immunity. Moreover, recognition is growing among vaccinologists for the challenges
involved in defining the correlates of vaccine-mediated protection against pathogens that
may require a combination of humoral and cellular immunity to develop an effective host
defense. T cells are key mediators of inflammatory processes that can be activated by
vaccine epitopes.

NIH-PA Author Manuscript

Although rare, some vaccine epitopes may cross-react with human/microbiome epitopes,
causing beneficial or detrimental effects. This phenomenon is known as heterologous
immunity. In regards to vaccine development, heterologous immunity can be exploited to
provide broad-based immunity to a family of related organisms. It can also describe epitopes
included in vaccines with the potential to induce unintended immune responses against
epitopes of human or human-associated (i.e. within the human microbiome) origin. The
identification of relevant pathogen epitopes and their comparison against other pathogen,
human and microbial genomic datasets are necessary steps to ensure that adaptive immune
responses elicited by a vaccine are both pathogen-specific and protective, but not crossreactive against host or commensal epitopes. Identification of cross-reactivities in vaccine
design will lead to safer and more effective vaccines.
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Heterologous immunity is a growing area of research that investigates more than the impact
of T cell-dependent cross-reactive immunity between species. In a larger sense, it considers
how past infections in individuals impact the shape immune responses take in later,
unrelated infections. For example, patterns of CD8+ T cell cross-reactivity between epitopes
encoded by Epstein Barr virus and influenza A virus in humans, and between vaccinia virus
and lymphocytic choriomeningitis virus in mice, are associated with varied disease states
observed in infection [24,25]. Interestingly, similar differences may also be influenced by
immunization. It was shown that vaccination with the bacillus Calmette-Guérin (BCG)
strain of Mycobacterium bovis, which is used to immunize against Mycobacterium
tuberculosis, induces CD4+ T cell-mediated resistance to vaccinia infection [26]. This is
significant because it implies that vaccine designers and clinicians should consider not only
the standard issues of safety and efficacy upon immunization in the present but also the
impact of immune memory on future immune responses to vaccination and natural infection.
Taken altogether, we believe it is important to document and evaluate the immunological
significance of epitope conservation and cross-reactivities between common vaccines and
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commensal and pathogenic microbes to understand the nexus between microbe and host. It
will require an understanding of immune responses using complementary experimental and
computational approaches, involving the latest tools for single cell analysis of cross-reactive
T cells [27] and immune system modeling [28]. Together, they will transform the current
qualitative understanding of heterologous immunity into a quantitative analysis that can be
used to predict beneficial and detrimental effects of immunization in individuals.
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Figure 1.

Genomes-to-Vaccine Strategy. Genomes are mined using computational and experimental
tools to identify genes that encode proteins with promising vaccine antigen properties such
as secretion, up-regulated expression and virulence. In silico. Immunoinformatics tools are
then used to map protein sequences for short, linear putative T cell epitopes. In vitro.
Candidates are synthesized as peptides and evaluated for MHC binding and antigenicity. In
vivo. Prototype epitope-based vaccines are evaluated for immunogenicity and protection in
humanized mice. Used with kind permission from Medicine and Health Rhode Island [29].
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Figure 2.
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Potential cross-reactive relationships among humans, commensal microbiota, and pathogens.
In the process of designing a vaccine the importance of choosing epitopes for inclusion is
balanced by the importance of choosing those to exclude. The definition of pathogenspecific epitopes for consideration in designing a new vaccine is a first step. To provide
further assurances of safety to the vaccinee, screening of pathogen-derived epitopes against
epitopes from the human genome and the microbiome is required. This secondary screening
of epitopes will lead to the exclusion of those pathogen epitopes that have the potential to
elicit immune reactions cross-reactive against the host or its commensal microbiota. These
types of cross-reactivities could lead to initiation of autoimmune syndromes or to disruption
of beneficial gut flora. Recent breakthroughs in high-throughput genomic analyses and
epitope prediction algorithms make these types of comparisons possible.
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